Prognostic Value of CD133 and SOX2 in Advanced Cancer.

Conclusions: CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed. Impact: CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients. PMID: 30693028 [PubMed]
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research